ICU Medical (NASDAQ:ICUI) Director Sells 378 Shares

ICU Medical, Inc. (NASDAQ:ICUIGet Free Report) Director Elisha Finney sold 378 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $182.48, for a total transaction of $68,977.44. Following the sale, the director directly owned 4,871 shares in the company, valued at $888,860.08. The trade was a 7.20% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

ICU Medical Trading Down 0.2%

NASDAQ ICUI traded down $0.34 on Tuesday, hitting $182.08. The company’s stock had a trading volume of 250,319 shares, compared to its average volume of 297,071. The company’s 50-day moving average is $152.66 and its 200 day moving average is $141.12. The firm has a market cap of $4.55 billion, a PE ratio of 154.31, a PEG ratio of 2.58 and a beta of 0.74. ICU Medical, Inc. has a 1-year low of $107.50 and a 1-year high of $192.85. The company has a quick ratio of 1.21, a current ratio of 2.43 and a debt-to-equity ratio of 0.56.

ICU Medical (NASDAQ:ICUIGet Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $2.37 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.46. The company had revenue of $547.88 million for the quarter, compared to analysts’ expectations of $533.44 million. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. ICU Medical’s revenue for the quarter was up .5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.10 earnings per share. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. As a group, analysts predict that ICU Medical, Inc. will post 6.51 earnings per share for the current fiscal year.

Institutional Trading of ICU Medical

Large investors have recently modified their holdings of the stock. Allworth Financial LP bought a new stake in shares of ICU Medical in the 2nd quarter valued at $26,000. Hilton Head Capital Partners LLC bought a new position in ICU Medical during the fourth quarter worth $32,000. Covestor Ltd grew its holdings in ICU Medical by 22.1% in the fourth quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock worth $99,000 after purchasing an additional 126 shares during the period. Strs Ohio increased its stake in ICU Medical by 60.0% in the fourth quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock valued at $114,000 after purchasing an additional 300 shares in the last quarter. Finally, Rockefeller Capital Management L.P. raised its holdings in shares of ICU Medical by 21.6% during the fourth quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock valued at $117,000 after purchasing an additional 146 shares during the period. Institutional investors and hedge funds own 96.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on ICUI shares. Piper Sandler lifted their price objective on ICU Medical from $163.00 to $195.00 and gave the stock an “overweight” rating in a research note on Friday. Jefferies Financial Group upgraded shares of ICU Medical to a “strong-buy” rating in a research report on Thursday, May 7th. Needham & Company LLC increased their price objective on shares of ICU Medical from $165.00 to $187.00 and gave the stock a “buy” rating in a research report on Friday. Zacks Research lowered shares of ICU Medical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 28th. Finally, Weiss Ratings raised shares of ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 23rd. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $192.80.

Read Our Latest Analysis on ICUI

About ICU Medical

(Get Free Report)

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

Read More

Insider Buying and Selling by Quarter for ICU Medical (NASDAQ:ICUI)

Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.